ANTIOS THERAPEUTICS
Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is focused on the development of its oral drug candidate for potentially curative treatment of HBV infections. Antios Therapeutics was founded by Abel De La Rosa, Douglas Mayers, and Idean Marvasty.
ANTIOS THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Therapeutics
Founded:
2018-01-01
Address:
Atlanta, Georgia, United States
Country:
United States
Website Url:
http://www.antiostherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
200.4 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Amazon SSL By Default Person Schema Microsoft Exchange Online Office 365 Mail Gravatar Profiles Microsoft Azure DNS
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Antharis Therapeutics
Antharis Therapeutics is a biopharmaceutical company developing therapies for unmet medical needs.
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Ocera Therapeutics
Ocera Therapeutics is a biopharmaceutical company developing novel therapeutics for patients with acute and chronic liver diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Silverback Therapeutics
Silverback Therapeutics is a biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways.
Simcha Therapeutics
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Current Advisors List
Current Employees Featured
Founder
Investors List
EPIQ Capital Group
EPIQ Capital Group investment in Series B - Antios Therapeutics
Altium Capital
Altium Capital investment in Series B - Antios Therapeutics
Domain Associates
Domain Associates investment in Series B - Antios Therapeutics
Heartland Healthcare Capital
Heartland Healthcare Capital investment in Series B - Antios Therapeutics
Pontifax
Pontifax investment in Series B - Antios Therapeutics
GRA Venture Fund
GRA Venture Fund investment in Series B - Antios Therapeutics
GordonMD Global Investments
GordonMD Global Investments investment in Series B - Antios Therapeutics
Avego Bioscience Capital
Avego Bioscience Capital investment in Series B - Antios Therapeutics
Fonds de solidaritรฉ FTQ
Fonds de solidaritรฉ FTQ investment in Series B - Antios Therapeutics
Amzak Health Investors
Amzak Health Investors investment in Series B - Antios Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-08-10 | Antios Therapeutics Appoints Catherine Coffey Ross as VP, Medical Affairs |
Official Site Inspections
http://www.antiostherapeutics.com Semrush global rank: 5.26 M Semrush visits lastest month: 1.47 K
- Host name: 104.21.63.147
- IP address: 104.21.63.147
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Antios Therapeutics"
Antios Therapeutics - Advancing Tomorrow & Therapies Today
Discover advanced osteoporosis treatments and bone health solutions at Antios Therapeutics. Our innovative therapies aim to improve bone density and enhance your quality of life.See details»
Antios Therapeutics - Crunchbase Company Profile
Contact Email [email protected] Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the company is โฆSee details»
Antios Therapeutics - LinkedIn
Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the โฆSee details»
Antios Therapeutics - Company Profile - Tracxn
Antios Therapeutics - Developer of innovative therapies to treat and cure viral diseases. Raised a total funding of $200M over 4 rounds from 23 investors. Founded by Abel De La Rosa and โฆSee details»
Antios Therapeutics Company Profile | Management and
[email protected]: Antios Therapeutics Top Competitors. Company Employees Revenue Top technologies; Chromis Therapeutics Inc. 9: $1.6 M: Arno Therapeutics Inc. 4: โฆSee details»
Antios Therapeutics Announces Agreement with IRBM, โฆ
Nov 15, 2021 For more information, please visit www.antiostherapeutics.com. About IRBM IRBM is a drug hunting company working primarily as an innovative contract research organization across all aspects of drug discovery and early โฆSee details»
Antios Therapeutics โ Funding, Valuation, Investors, News
Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership team, the โฆSee details»
Antios Therapeutics CEO and Key Executive Team | Craft.co
Antios Therapeutics's President and Chief Executive Officer is Greg Mayes. Other executives include Patrick Higgins, Director; Doug Mayers, Chief Medical Officer and 10 others. See the โฆSee details»
Antios Therapeutics - Craft
Antios Therapeutics is a biopharmaceutical company that specializes in therapies for hepatitis B virus (HBV) and other viral diseases. It develops active site polymerase inhibitor nucleotide โฆSee details»
Nextsource | Company Profile | Antios Therapeutics
Explore the company profile of Antios Therapeutics (antiostherapeutics.com) featuring business details and insights, funding data, industry info, employee numbers, and more.See details»
Antios Therapeutics - VentureRadar
Website: http://www.antiostherapeutics.com/ Antios Therapeutics is a biopharmaceutical company devoted to developing innovative therapies for viral diseases.See details»
Antios Therapeutics (USA) Funding: $200.4M - medicalstartups.org
Antios Therapeutics is a biopharmaceutical company developing innovative therapies for viral...See details»
Antios Therapeutics to acquire fourth-generation HBV capsid
For more information, please visit www.antiostherapeutics.com www.antiostherapeutics.com. About IRBM. IRBM is a drug hunting company working primarily as an innovative contract โฆSee details»
Antios Therapeutics Inc Overview - Salary.com
Discover essential details about Antios Therapeutics Inc, including address, contact, and journey of our company's evolution.See details»
Antios Therapeutics Announces Agreement with IRBM, INGM and โฆ
Nov 15, 2021 For more information, please visit www.antiostherapeutics.com. About IRBM ... Now in its 11th year as an independent research organization, IRBM has laid the foundations โฆSee details»
Antios Therapeutics Appoints Gregory T. Mayes Chief Executive โฆ
Dec 1, 2020 Former CEO and Antios co-founder, Abel De La Rosa, Ph.D., appointed Chairman of the Board of Directors Mayes to lead continued development of ATI-2173 as a potential โฆSee details»
Antios Therapeutics Raises $75 Million in a Series B-1 Funding to ...
MENDHAM, N.J., Nov. 3, 2021 /PRNewswire/ -- Antios Therapeutics, Inc. ("Antios"), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic โฆSee details»
Hep B biotech Antios closed after FDA hold proved insurmountable
Sep 22, 2023 Assembly also ended its quest for a functional cure of hepatitis B with vebicorvir in July 2022 after lackluster data showed the core inhibitor was unlikely to succeed. The โฆSee details»
Antios Therapeutics โ Funding, Valuation, Investors, News
Nov 4, 2021 Antios Therapeutics is a clinical-stage biopharmaceutical company devoted to developing innovative therapies for viral diseases. With an experienced and proven leadership โฆSee details»
Antios Therapeutics, Inc. (Antios Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธ โฆ
This study is a single-center, open-label, 2-cohort, fixed-sequence, DDI study in healthy adult subjects. Healthy volunteers will be administered multiple oral doses of ATI-2173 in โฆSee details»